|Bid||6.53 x 1400|
|Ask||7.01 x 2200|
|Day's Range||6.46 - 7.09|
|52 Week Range||3.00 - 8.65|
|Beta (5Y Monthly)||1.11|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for CNTA
The average of price targets set by Wall Street analysts indicates a potential upside of 40.9% in Centessa Pharmaceuticals PLC Sponsored ADR (CNTA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
The consensus price target hints at a 35.9% upside potential for Centessa Pharmaceuticals PLC Sponsored ADR (CNTA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Key Clinical Trials Advance as Centessa Pharmaceuticals PLC (CNTA) Manages Expenses